本文選題：哮喘 + 基因芯片��； 參考：《南華大學》2013年碩士論文

【摘要】：目的 利用全基因表達譜芯片技術觀察哮喘大鼠和應用三氧化二砷干預后不同時間點的基因差異表達的變化，闡明哮喘的發(fā)病機制和三氧化二砷治療哮喘的分子機制。 方法 健康雄性清潔級SD大鼠70只，，按隨機表隨機分成3組：正常對照組A組10只，哮喘模型組B組30只(分別為二周B1組、四周B2組、八周B3組，每組各10只），三氧化二砷干預組C組30只(分別為二周C1組、四周C2組、八周C3組，每組各10只）。以腹腔內注射聯合霧化吸入卵蛋白建立哮喘模型，末次激發(fā)后24h處死大鼠檢測支氣管肺泡灌洗液（BALF）中的白細胞數及嗜酸性粒細胞數；左肺行染色、病理圖像分析；再切取右肺提取肺組織總RNA行全基因組表達譜芯片檢測，以基因表達倍數值2.0和基因表達倍數值－2.0為閾值來確定差異表達基因，然后用GO及Pathway分析對差異表達基因進行功能分類分析，并對基因芯片結果進行實時定量PCR驗證。 結果 1、哮喘模型組BALF中白細胞總數、嗜酸性粒細胞（Eos）比例較正常組均有明顯增高，三氧化二砷組較哮喘模型組明顯降低，差異有顯著性(P 0.05)。 2、哮喘模型組大鼠氣道支氣管及血管周圍存在大量炎癥細胞浸潤，以嗜酸性粒細胞、淋巴細胞為主，氣道平滑肌增厚，基底膜增厚，管腔狹窄，粘膜下細胞外基質沉積，且隨著時間的延長，以上變化逐漸加重；三氧化二砷組較哮喘模型組上述改變減輕，正常組無上述改變。 3、在24358個基因表達譜的篩選中，哮喘模型組對比正常組共有438個差異基因表達，其中348個上調，90個下調；三氧化二砷組對比哮喘模型組共有236個基因表達差異，其中96個上調，140個下調。其中GZMA、MAL基因在哮喘模型組中表達下調，三氧化二砷干預組后表達上調，通過實時定量PCR驗證后與基因芯片篩選結果表達方向一致。 結論 1、GZMA、MAL等基因可能參與了哮喘的發(fā)生發(fā)展過程。 2、三氧化二砷治療哮喘的機理可能與上調GZMA、MAL基因在肺組織中的表達有關。
[Abstract]:Purpose In order to elucidate the pathogenesis of asthma and the molecular mechanism of arsenic trioxide treatment, the changes of gene differential expression at different time points after arsenic trioxide intervention in asthmatic rats were observed by whole gene expression microarray technique. Method Seventy healthy male SD rats of clean grade were randomly divided into three groups: normal control group (n = 10), asthma model group (B group) (n = 30) (group B _ 1 for two weeks, group B _ 2 for four weeks, group B _ 3 for eight weeks). There were 10 rats in each group, and 30 rats in group C in arsenic trioxide intervention group (10 rats in each group) (C1 group for two weeks, C 2 group for four weeks and C 3 group for eight weeks). The asthmatic model was established by intraperitoneal injection and atomization inhalation of ovalbumin. The white blood cells and eosinophils in bronchoalveolar lavage fluid (BALF) were measured 24 hours after the last stimulation, and the left lung was stained and analyzed by pathological images. The total RNA of lung tissue was extracted from the right lung and detected by whole genome expression microarray. The differentially expressed genes were determined by the threshold of gene expression doubling value 2.0 and gene expression doubling value -2.0. Then go and Pathway analysis were used to analyze the function of differentially expressed genes, and real-time quantitative PCR was used to verify the results of gene chip. Result 1. The percentage of total white blood cells and eosophils in BALF of asthmatic model group was significantly higher than that of normal group, and that of arsenic trioxide group was significantly lower than that of asthmatic model group (P 0.05). 2. In the asthma model group, there were a large number of inflammatory cells infiltrating around the airway bronchus and blood vessels, mainly eosinophils and lymphocytes, airway smooth muscle thickening, basement membrane thickening, lumen stenosis, and extracellular matrix deposition. The above changes were gradually aggravated with the prolongation of time, and the above changes in arsenic trioxide group were lighter than those in asthma model group, but no such changes were found in normal group. 3. In the screening of 24358 gene expression profiles, there were 438 differentially expressed genes in asthmatic model group compared with normal group, 348 of which were up-regulated and 90 were down-regulated, and 236 genes were differentially expressed in arsenic trioxide group compared with asthmatic model group. Of these, 96 were up-regulated and 140 downgraded. The expression of GZMA-MAL gene was down-regulated in asthmatic model group and up-regulated in arsenic trioxide intervention group. The expression direction of GZMA-MAL gene was consistent with the result of gene chip screening by real-time quantitative PCR. Conclusion Genes such as GZMA-MAL may be involved in the occurrence and development of asthma. The mechanism of arsenic trioxide in the treatment of asthma may be related to the up-regulation of GZMA-MAL gene expression in lung tissue.
【學位授予單位】：南華大學
【學位級別】：碩士
【學位授予年份】：2013
【分類號】：R562.25

【共引文獻】

相關期刊論文 前4條

1 劉明;朱倫華;�？�;劉洪俊;;急性心肌梗死血清C反應蛋白檢測臨床意義探討[J];蚌埠醫(yī)學院學報;2010年09期

2 賈勤;;C反應蛋白與急性心肌梗死預后的關系[J];長治醫(yī)學院學報;2009年05期

3 張成祿;謝健敏;王前;鄭磊;;急性心肌梗死易感基因多態(tài)性研究現狀[J];檢驗醫(yī)學與臨床;2009年14期

4 趙錳;趙京;戴耀華;;哮喘基因新進展[J];中華臨床免疫和變態(tài)反應雜志;2009年02期

相關博士學位論文 前6條

1 王明松;對氧磷酶基因多態(tài)性與冠心病的關聯分析及薈萃分析[D];第二軍醫(yī)大學;2011年

2 李俊燕;常見精神疾病共享遺傳風險研究[D];上海交通大學;2011年

3 田朝偉;中國漢族人群冠狀動脈粥樣硬化性心臟病與基因多態(tài)性的關聯研究[D];廣州醫(yī)學院;2011年

4 韓士忠;雙色熒光正相雜交檢測SNP動力學初探及復雜疾病易感基因的關聯分析和Meta-分析[D];復旦大學;2006年

5 黃克;精神分裂癥及糖尿病視網膜病變的連鎖不平衡分析[D];上海交通大學;2009年

6 趙倩;遺傳變異與精神疾病的關聯分析[D];上海交通大學;2010年

相關碩士學位論文 前4條

1 黃漢琮;ORMDL3基因rs7216389位點多態(tài)性與哮喘相關性研究[D];南昌大學;2011年

2 賀藏棟;精神分裂癥易感位點的關聯分析和薈萃分析[D];上海交通大學;2008年

3 古博;利培酮臨床藥效和HTR3A基因的關聯研究[D];上海交通大學;2008年

4 姚青剛;可溶性半乳糖凝集素2基因多態(tài)性與動脈硬粥樣硬化性腦梗死相關性研究[D];河北醫(yī)科大學;2010年

本文編號：1838762